R. T. Chung and T. F. Baumert, Curing chronic hepatitis C--the arc of a medical triumph, N Engl J Med, vol.370, issue.17, pp.1576-1578, 2014.

, Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Guideline on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis

. Accessed, , 2019.

B. L. Pearlman and N. Traub, Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more, Clin Infect Dis, vol.52, issue.7, pp.889-900, 2011.

R. L. Morgan, B. Baack, B. D. Smith, A. Yartel, M. Pitasi et al., Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies, Ann Intern Med, vol.158, issue.5, pp.329-337, 2013.

F. Carrat, H. Fontaine, and C. Dorival, Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study, Lancet, vol.393, pp.1453-1464, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02050395

D. K. Li, Y. Ren, and D. S. Fierer, The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study, Hepatology, vol.67, issue.6, pp.2244-2253, 2018.

A. R. Feinstein, D. M. Sosin, and C. K. Wells, The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer, N Engl J Med, vol.312, issue.25, pp.1604-1608, 1985.